SWA
ABBV icon

Stratos Wealth Advisors’s AbbVie ABBV Stock Holding History

Stratos Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.36M Sell
15,459
-445
-3% -$98.7K 0.21% 105
2025
Q4 		$3.63M Buy
15,904
+38
+0.2% +$8.66K 0.18% 129
2025
Q3 		$3.67M Buy
15,866
+1,073
+7% +$219K 0.18% 130
2025
Q2 		$2.75M Sell
14,793
-69
-0.5% -$12.8K 0.14% 145
2025
Q1 		$3.11M Sell
14,862
-9,297
-38% -$1.81M 0.17% 125
2024
Q4 		$4.29M Buy
24,159
+58
+0.2% +$10.7K 0.21% 112
2024
Q3 		$4.76M Buy
24,101
+18
+0.1% +$3.36K 0.22% 102
2024
Q2 		$4.13M Sell
24,083
-516
-2% -$85.5K 0.2% 112
2024
Q1 		$4.48M Sell
24,599
-34,752
-59% -$5.99M 0.27% 91
2023
Q4 		$9.2M Sell
59,351
-2,877
-5% -$419K 0.53% 30
2023
Q3 		$9.28M Buy
62,228
+10,205
+20% +$1.5M 0.61% 26
2023
Q2 		$7.01M Sell
52,023
-227
-0.4% -$33.3K 0.5% 38
2023
Q1 		$8.33M Sell
52,250
-695
-1% -$106K 0.64% 23
2022
Q4 		$8.56M Buy
52,945
+1,953
+4% +$299K 0.71% 22
2022
Q3 		$6.84M Sell
50,992
-4,191
-8% -$601K 0.72% 23
2022
Q2 		$8.45M Buy
55,183
+229
+0.4% +$35K 0.77% 18
2022
Q1 		$8.91M Sell
54,954
-3,400
-6% -$494K 0.72% 22
2021
Q4 		$7.9M Buy
58,354
+742
+1% +$87.6K 0.57% 35
2021
Q3 		$6.21M Sell
57,612
-488
-0.8% -$55.8K 0.53% 38
2021
Q2 		$6.54M Buy
58,100
+2,643
+5% +$298K 0.58% 30
2021
Q1 		$6M Sell
55,457
-3,462
-6% -$370K 0.64% 28
2020
Q4 		$6.31M Buy
58,919
+6,065
+11% +$583K 0.87% 18
2020
Q3 		$4.63M Buy
52,854
+426
+0.8% +$40.1K 1.13% 20
2020
Q2 		$5.15M Buy
52,428
+42,460
+426% +$3.74M 1.58% 11
2020
Q1 		$759K Buy
9,968
+529
+6% +$45.1K 0.54% 52
2019
Q4 		$836K Sell
9,439
-2,040
-18% -$169K 0.47% 52
2019
Q3 		$869K Buy
11,479
+233
+2% +$16K 0.33% 79
2019
Q2 		$818K Buy
11,246
+227
+2% +$17.8K 0.33% 74
2019
Q1 		$888K Buy
11,019
+26
+0.2% +$2.13K 0.48% 54
2018
Q4 		$1.01M Buy
+10,993
New +$967K 0.68% 35

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stratos Wealth Advisors's ABBV Position: Q1 2026 in Review

Stratos Wealth Advisors reduced its AbbVie (ABBV) stake by 2.8% in Q1 2026, selling an estimated $98.7K and leaving 15,459 shares worth $3.36M. The position accounts for 0.21% of the portfolio, ranked #105.

Stratos Wealth Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $9.28M in Q3 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Stratos Wealth Advisors held 15,459 shares of AbbVie worth $3.36M as of Q1 2026.
  • Stratos Wealth Advisors sold 445 AbbVie shares in Q1 2026, an estimated $98.7K.
  • AbbVie made up 0.21% of Stratos Wealth Advisors's portfolio in Q1 2026, its #105 holding.
  • Stratos Wealth Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Stratos Wealth Advisors's AbbVie position peaked at $9.28M in Q3 2023.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.